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DEDICATION 
 
 
To all the fighters –  
 
A disease may be rare, but hope should not be. 
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      Background:  
 Amyotrophic lateral sclerosis (ALS) is a fatal neurologic disease that is projected to 
double in worldwide incidence in the next 20 years. The heterogenic nature of the disease and 
relatively limited research data, compared to non-rare diseases, have made it difficult for 
clinician researchers to alter the course of the disease within the short life expectancy after 
symptom onset.   
Methods: 
 This was a mixed-method retrospective review and live sampling study using three 
distinct data sources. Retrospective data was abstracted from the electronic medical record 
systems for a select group of ALS patients seen at the University of California, Irvine 
Neuromuscular Center (UCI NMC). Additional retrospective datasets curated by the Pooled 
Resources Open-Access Clinical Trials (PRO-ACT) database were also analyzed. Observational 
data was collected using a 9-item survey developed on Google Forms and disseminated through 
the ALS Association Golden West Chapter. The items measured symptom onset, diagnostic 
journey, and patient demographics.    
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Results:  
The analyses confirmed current reports of higher disease incidence in Caucasian 
populations, usually comprising at least 60% of each dataset. The gender prevalence towards 
males was only observed in the PRO-ACT dataset. There was also a difference in mean age 
between PRO-ACT (56 years), UCI (61 years), and Online Questionnaire respondents (66 years).   
Discussion:  
Ultimately retrospective data analyses were limited by substantial missing, not at random 
data. Large data repositories can bridge the gap between non-rare and rare disease research, but 
only with robust and methodologic data collection across all participating sites.   
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INTRODUCTION 
As populations continue to age in developing nations, future projections estimate the 
number of people afflicted with ALS will nearly double to 800,000 worldwide by 2040. The 
variable phenotypic presentations and rates of functional decline prove challenging for clinician 
researchers to alter the disease course in the relatively short life expectancy following disease 
onset. Researchers and patients alike hope to see a breakthrough therapy emerge, but only 20% 
of the past 50 ALS trials have evolved to late-stage development; only one is currently 
continuing its late-stage development. The ongoing clinical practice is to treat ALS as a 
homogeneous disease, addressing symptoms as they arise; however, this approach fails to 
account for the broad spectrum of survival between patients. A group in the United Kingdom 
developed a model for predicting survival based on known factors linked to survival; however, 
the model is restricted to patients of European ancestry and does not include any patient 
demographics beyond ALS traits. 
Considering the varying prognosis between patients, identifying predictors of survival is 
crucial to improving clinical trial outcomes, providing personalized care, and bettering overall 
quality of life. In this thesis, the following questions will be addressed:  
Question 1: Will an in-depth analysis of the PRO-ACT database confirm the longstanding 
average demographics associated with ALS?  
Hypothesis 1:  The PRO-ACT database will trend towards younger patients, but still Caucasians 
and males will predominate the demographic characteristics of that sample with 50% of survival 
beyond five years from symptom onset. 
Question 2: Are there associations between patient characteristics (i.e., race/ethnicity, gender) 
and the incidence of ALS, rate of decline, and mortality?  
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Hypothesis 2: The PRO-ACT database will have greater incidence of ALS in non-minorities and 
males, but equal rate of decline and mortality independent of these characteristics.  
Question 3: Will the observational data from the patient survey identify trends associated with 
diagnostic delay or patient characteristics?   
Hypothesis 3: The diagnostic delay in the observational population will be shorter than that seen 
in the PRO-ACT dataset and patient characteristics will align with those of the national averages.  
 In addressing these questions, the results from this study may update current 
demographics and help develop a prognostic survival model applicable to all patients with ALS. 
Additionally, it will identify problem areas in ALS clinical trials and improve the design of 
future trials. 
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BACKGROUND 
Amyotrophic lateral sclerosis (ALS) is a progressive, neurodegenerative disease affecting 
upper and lower motor neurons in the brain stem, motor cortex, and spinal cord. Motor neurons 
extend from the brain to the spinal cord and to the muscles throughout the body. They initiate 
and serve as the communication relay between the brain and the voluntary muscles (Figure 1). 
This relay is disrupted in patients with ALS, which causes the muscles to gradually weaken. 
Over time the brain loses its ability to initiate and control all voluntary movements (1). The 
progressive loss of motor neurons clinically presents as myasthenia, atrophy, spasticity, 
dysphagia, dysarthria, and dyspnea. Patients afflicted with this terminal disease suffer total 
paralysis and usually die from complications secondary to respiratory failure. Current data 
suggests that the average life expectancy for a person with ALS is three to five years from the 
time of symptom onset.  
Figure 1. Types of Motor Neurons 
 
 Prior to receiving a diagnosis, most patients will see multiple physicians, possibly 
receiving one or two misdiagnoses along the way. A recent study by Paganoni reviewed such 
data for 304 subjects and found that the median total diagnostic time was 11.5 months (IQR: 7-
20 months). A subset of patients (n=122) had data available for median time from presenting 
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symptom to first doctor visit (four months, IQR: 2-7 months) and first doctor visit to suspected 
ALS diagnosis (three months, IQR: 1-6, n=100). The study found that approximately 52% 
received at least one other diagnosis before ALS was confirmed. Additionally, each patient saw 
an average of three physicians before ALS was confirmed. In most cases, the diagnosis was first 
suspected by either a general neurologist (57%) or an ALS specialist (20%) but confirmed by an 
ALS specialist in 85% of cases and by a general neurologist in 12% of cases (2). One of the 
factors adding to the diagnostic delay is that early symptoms are difficult to differentiate from 
other neurological illnesses. Early symptoms of ALS include weakness to a muscle region, 
fasciculations and/or cramps, tripping, decreased dexterity, slurred speech, muscle spasticity, and 
difficulty chewing or swallowing. Current data suggests that the average life expectancy for a 
person with ALS is two to five years from the time of diagnosis. However, half of all affected 
live at least three years, 20% live five years or more, and up to 10% survive for more than 10 
years. (3) The survival variability between patients was best demonstrated by a study of 30 
randomly selected ALS patients at the Leuven University Hospital in Belgium. As seen in Figure 
2, in plotting the ALSFRS-r scores from first visit to death, the Swinnen study supported the 
concept of ALS as highly heterogeneous. (4) 
Figure 2. Heterogeneity of Disease Progression Between ALS Patients 
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1.1 Disease Incidence  
The FDA define a rare disease as one that affects fewer than 200,000 people in the U.S. 
At this time, ALS still meets this criterion; however, as previously mentioned, future projections 
will shift it out of this designation. A unique project conducted by the Texas State Department of 
Health Services studied Texas-specific epidemiological data regarding ALS. Interestingly, each 
of the large metropolitan areas studied showed increasing incidence rates every year, with an 
average of 325 new cases per year. (5) This localized increase is similar to that projected for the 
national average established by the congressionally mandated National ALS Registry. 
Furthermore, as recently demonstrated by a review of worldwide ALS incidence, the disease 
exhibits a heterogeneous distribution with notably lower reported incidences in South Asia 
([0.58-0.89]/100,000 person-years) and higher reported incidences in North Europe ([1.46-
2.32]/100,000 person-years). (6) This review is set apart from other ALS epidemiology studies 
because it is one of the few meta-analyses conducted in this population. Even so, there were 
several limitations that impacted the overall incidence report rates, particularly with U.S. data 
acquisition. Cases from the U.S. spanned from 2009-2011, prior to and in the early phase of the 
National ALS Registry.  
As exemplified by the several long-standing and robust European registries that have 
engendered the predictive survival model, the value of a disease registry is considerable. 
Unfortunately, the National ALS Registry has three substantial flaws that must be addressed for 
viable data use. First, researchers cannot access data in the registry as “it does not yet contain 
enough data to be useful to most researchers.” (7) Thus, after a decade of existence, the data 
remains accessible only to the Agency for Toxic Substances and Disease Registry (ATSDR) with 
periodic data released by the Centers for Disease Control and Prevention (CDC). Second, also of 
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concern for the registry is its heavy dependence upon household access to the internet to 
complete initial and interval questionnaires. Of the total 2015 Census household respondents, 
nearly 35.5% of non-Hispanic, Black households and 29.5% of Hispanic (any race) households 
responded as not having any internet subscription. (8) As such, the incidence rate is likely higher 
than currently reported. Lastly, despite being congressionally mandated, registry enrollment 
remains voluntary in all states except Massachusetts.  
1.2 Race and Ethnicity  
ALS has higher prevalence in non-Hispanic whites than any other group. Given the rarity 
of the disease, incidence is often calculated from mortality data. Previously epidemiologic 
studies suggest there are race/ethnicity discrepancies in patients diagnosed with ALS. The largest 
sample size reported to date was a recent study conducted at the Massachusetts General Hospital 
which obtained mortality information through the National Longitudinal Mortality Study 
(NLMS) and the National Death Index (NDI) to determine whether race/ethnicity and 
socioeconomic status (SES) are associated with ALS mortality in the United States. The study 
observed higher rates of ALS among whites compared to other race/ethnicity groups. (9) 
However, as the NLMS relies on data collected through the Census report, the dependence upon 
the Census response rate introduces a potential bias. The CDC lists ALS prevalence rates 
calculated for the four U.S. Census regions with the rates, per 100,000 population, as follows: 
Midwest (5.7), Northeast (5.5), South (4.7), West (4.3). (10) Historically, the response rate 
remained below 70% until the 2000 Census. Although the Census is meant to count every 
person, not legal citizen, unauthorized residents fear that participation will expose them to 
immigration raids or government harassment. (11) Consequently, prevalence rates of ALS in the 
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South and West may be underreported, which is significant when taking into consideration that 9 
out of 10 of America’s most diverse metros are in just these two regions. (12)   
Although the specific racial/ethnic disparity was possibly confounded by Census 
methods, the Roberts study did conclude this rate is likely reflective of actual higher risk of ALS 
rather than the effect of SES on risk, thus placing heavier emphasis on the influence of 
racial/ethnic background. (9) These data further supported the role of race/ethnicity and its 
involvement in ALS.  
1.3 Disease Management 
 Since its discovery in 1869 by Jean-Martin Charcot, the actual mechanism behind the 
development of ALS largely remains a mystery making the treatment of it an enigma. There are 
currently two FDA approved therapies for this disease, Riluzole (Rilutek®) and Edaravone 
(Radicava®); however, neither are considered therapeutically beneficial. 
1.3.1 Riluzole (Rilutek®)  
In 1995, this glutamate blocker was the first FDA approved treatment for ALS; however, 
there are several limitations that prevent it from being an effective standard of care therapy. The 
exact average of ALS patients in the United States taking Riluzole (Rilutek®) is widely variable 
between reports, ranging between 50% to 75%. (1) Some patients cannot tolerate the known side 
effects (e.g., gastrointestinal disturbances, lethargy) or must discontinue use due to the drugs 
known hepatotoxicity effects. However, most patients opt not to take it because the added 3-5 
months of life combined with the $6 daily cost even for the generic version makes it difficult for 
most patients to use. (13,14)  
1.3.2 Edaravone (Radicava®)  
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In 2017, the FDA approved a repurposed stroke therapy from Japan, for use in all patients 
with ALS without requiring any clinical trials in the U.S. The data from Japan’s phase 3 clinical 
trial faced outside criticism for enrolling ALS patients who were early on in their disease with 
overall better functionality. Additionally, the drug carries a hefty $148,000 price tag per year of 
treatment. Medicare and Veterans Administration offers coverages upwards of 80%, but public 
insurance programs do not provide any coverage. (15) There are also additional costs associated 
with drug administration staff resources, as well as, placing and maintaining a central venous 
catheter for the monthly infusions. Lastly, the treatment itself can be burdensome to patients; it 
requires monthly infusion cycles, administered over a 10-day period. Although home infusions 
are possible, remote clinic infusions are not; thus vacations, family time, and other social 
activities either decrease or halt to accommodate the cycles. Consequently, within the first year, 
less than 10% of Americans with ALS accessed Radicava and fewer still have continued 
treatment with it. (15) 
 Given the limited treatment options, the standard of care predominantly focuses on 
palliative care methods such as, non-invasive ventilation (NIV), percutaneous endoscopic 
gastrostomy (PEG) tube feeding, and assistive devices to aid patients as the disease progresses. 
1.3.3 Respiratory Function  
Maintaining respiratory function is of utmost importance in patients with ALS as it 
affects daily quality of life and overall disease outcome. Consequently, monitoring respiratory 
decline and initiating NIV such as BiPAP or Trilogy in a timely manner is key to minimizing 
prolonged respiratory distress. In comparison to tracheostomy-free ALS patients who never used 
NIV during the course of their disease, overall median survival benefits are as great as 13 months 
[HR=0.61; p<0.001], regardless of site of onset. (16) Bulbar-onset patients, for whom respiratory 
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decline doubles the monthly risk of mortality compared to limb-onset patients, experience 
survival benefits as high as 19 months [HR=0.50; p<0.001]. (16; 17) Despite the overall upper 
limit survival benefit almost three times that of Riluzole, many insurance companies in the 
United States will not approve NIV coverage until pulmonary function tests indicate severe 
respiratory restriction.  
1.3.4 Dysphagia  
PEG tubes allow for a safe and effective method of providing enteral feeding to the 
extent of the patient’s dysphagia involvement (i.e., NPO, partial, medication administration). 
Since the placement procedure is done under general anesthesia, it must be done prior to 
respiratory impairment falling within the severe criterion. A post-mortem analysis of 83 patients 
in the U.S. revealed a significant survival benefit [HR=0.24; p<0.01] in the patients with a PEG, 
after adjusting for covariates (e.g., age, site of onset). (18) However, due to the lack of larger 
scale data to support it, the overall effect on survival remains a topic of debate. Regardless, 
alleviating the consequences of dysphagia cannot be underestimated.  
1.3.5 Assistive Devices  
As patients develop deficits to mobility and communication, assistive devices become 
crucial to support remaining motor function. Assistive devices include items such as manual or 
power wheelchairs, orthoses, home adaptations, and augmentation and alternative 
communication (AAC). (19) The procurement of these various modifiers depends on healthcare 
access, geographic location, and insurance approvals. One study followed almost 1500 patients 
across 12 ALS centers in Germany found that 54.8% of patients needed 5 or more assistive 
devices, but 29.8% of these devices were not procured. Like U.S. trends, the more complex and 
expensive the device, the less likely it was to be obtained. The procurement rates were lowest for 
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transfer systems like lifts and ramps (40.3%), AAC devices (38.8%), and power wheelchairs 
(38.5%). Even though patients report these devices as the ones that provide the highest 
satisfaction and usefulness (20), the primary cause of failed procurement was insurance rejection 
(50.9%), followed by patient noncomformity (29.5%), and finally patient death before 
procurement (19.6%). (21)  
 The ongoing clinical practice is to treat ALS as if the disease is a homogeneous disease; 
however, this approach fails to appreciate and investigate the broad spectrum of survival. The 
variability in survival between patients is best supported by addressing the heterogeneous nature 
of the disease, both in the phenotypic presentation and varying rates of functional decline. Recent 
studies based out of the United Kingdom have developed a model of predicting survival based on 
known factors linked to survival. Unfortunately, this model is restricted to patients of European 
ancestry and does not include any patient demographics beyond ALS traits. Considering the 
varying prognosis between patients, identifying predictors of survival based on an individual 
patient’s demographics and ALS characteristics is key to providing more personalized care. 
Novel epidemiological studies have helped the neuromuscular community provide average 
prognoses to newly diagnosed patients and identify subgroup differences. Trials in rare diseases 
frequently have smaller sample sizes due to the limited pool of eligible patients. (22) The 
creation of large-scale databases complements the ongoing efforts of clinical trials in rare 
diseases like ALS. 
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METHODS 
2.1 University of California, Irvine (UCI) Neuromuscular Center (NMC) 
 The study design planned for retrospective review of serial data collected from January 1, 
2013 through January 1, 2018. Even though the UCI NMC database continues to collect 
prospective data as part of clinical care, the analysis for this study was restricted to the specified 
time-period to ensure enough longitudinal data points per subject. The retrospective study using 
UCI data was submitted to and approved by UCI’s local Institutional Review Board (IRB) under 
Expedited Category 5: research involving materials (data, documents, records, or specimens) that 
have been collected, or will be collected solely for non-research purposes (such as medical 
treatment or diagnosis). UCI Health Enterprise Data & Analytics maintains and oversees the 
Enterprise Data Warehouse which integrates data from the EMR, Professional Billing, Hospital 
Billing, and other administrative systems. UCI Health’s Honest Broker service runs Enterprise 
Data Warehouse queries using filters such as diagnosis codes and billing codes and returns de-
identified results for IRB approved research use.  
Patients were identified using the ninth (ICD-9) and tenth (ICD-10) revisions of the 
International Statistical Classification of Diseases and Related Health Problems diagnosis codes 
for ALS, 335.20 and G12.21, respectively.  
2.2 Northeast Amyotrophic Lateral Sclerosis (NEALS) Consortium  
 As a melting pot country, the United States health system is posed with the challenge of 
multi-ethnic backgrounds and demographics that are likely not covered in the current body of 
literature. Despite its name, the NEALS consortium is composed of over 100 research centers 
across the country dedicated to translating scientific advances into new treatments and quality 
improvement projects. The Pew Research Center estimates that 11.1 million of the nation’s 
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unauthorized immigrants live in just 20 major metropolitan areas, with California and Texas 
account for five and three areas, respectively. Figure 3 depicts the NEALS research centers 
superimposed with the most diverse metropolitan areas in America as well as those recorded as 
having the most unauthorized immigrants. (11; 12)  
Figure 3. Map of NEALS Sites vs. Most Diverse Metro Areas vs. Most Unauthorized 
Immigrants 
 
2.3 Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) Database  
As a prominent clinical trial center, UCI NMC is a part of several neuromuscular 
collaborative research networks including the NEALS consortium. A partnership between 
NEALS, Prize4Life, Neurological Clinical Research Institute (NCRI) at MGH engendered the 
PRO-ACT database. The platform houses over 8500 ALS patient records from multiple 
completed clinical trials. The initiative merges data from existing publicly- and privately-
conducted ALS clinical trials to provide those with an interest in moving ALS research forward 
quickly with a powerful tool.  
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PRO-ACT provides researchers with access to over 10,000 de-identified records for 
patients who took part in a clinical trial. The database is composed of data from 23 Phase II/III 
clinical trials that had placebo and treatment-arm data. Datasets are available for more than 10 
million longitudinally collected data points including demographics, lab, medical and family 
history and other data elements. (23)    
2.3.1 PRO-ACT Database Design  
The initial database was composed of all phase II and III ALS clinical trials completed 
between 1990 and 2010 with at least 80 subjects enrolled. Key decision markers for each trial 
were contacted and asked to donate de-identified trial datasets. A common data structure was 
created for the data that was categorized as “common” among the eligible trials. The data went 
through extensive cleaning to become as cohesive as possible for the final database. The result 
was longitudinal data from 16 trials on 8635 people with ALS, including 11 distinct data 
categories totaling 8 million data points. (23) This large database allows researchers to utilize 
network models, machine learning algorithms for clustering, predicting and stratifying data that 
was otherwise not possible to explore in ALS research.  
2.3.2 PRO-ACT Database Advantages 
The first large-scale example of this was the 2012 DREAM-Phil Bowen ALS prediction 
Prize4Life challenge. The challenge was a collaboration between Prize4Life and The DREAM 
Project (Dialogue for Reverse Engineering Assessments and Methods) that invited solvers to 
build algorithms utilizing three months of data to predict disease progression nine months later. 
Over 1000 registrants from 64 countries took part in the challenge. The resulting algorithms not 
only identified new potential predictors of ALS progression, but has the potential to reduce the 
required sample size for clinical trials by at least 20%. (24) 
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 As mentioned before, ALS epidemiology studies heavily rely on death certificates and 
registry data because there is no clinical test to determine if a person has the disease. Given this 
limitation, ALS is often misdiagnosed and the validity of epidemiological conclusions using 
mortality data is questionable. A study in South Carolina inspected the medical records of 
patients identified in the state’s morbidity data with the ALS ICD-10, G12.2, that 85% had 
supporting diagnostic documentation in their charts, but only 65% of death certificates were 
coded with an ALS linking cause of death; 18% had an ‘alternative neurological diagnosis’ as 
the cause of death. (25) The retrospective study was able to circumvent this problem because all 
cases come from the PRO-ACT database where the patients have been confirmed by an expert 
neurologist as having the disease.  
2.4 Outcome Measures 
 The progressive symptoms of ALS and functional decline are measured by way of the 
ALS Functional Rating Scale revised [ALSFRSr] (Figure 4), which measures gross and fine 
motor function, bulbar function, and respiratory function. In the clinic setting, patients complete 
this patient reported outcome (PRO) with a certified evaluator, as well as forced vital capacity 
(FVC) tests with a licensed respiratory therapist. The FVC is a measurement of lung size (in 
liters) and represents the volume of air in the lungs that can be exhaled following a deep 
inhalation (Figure 5). The results, presented in liters, are compared to what is expected for 
someone of the same sex, age and height; the resulting calculation is the percent vital capacity. 
Lower percentages are indicative of diaphragmatic weakness while seated and/or supine.  
 Both the ALSFRSr and FVC commonly serve as the primary or secondary endpoint in 
ALS clinical trials. They also serve as valuable red flags for initiating NIV, PEG tube placement, 
and obtaining orthotics and other adaptive equipment for patients as they progress.  
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Figure 4. Amyotrophic Lateral Sclerosis Functional Rating Score - revised (ALSFRSr) 
 
Figure 5. Forced Vital Capacity (FVC) 
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2.5 Retrospective Data Collection 
The following data was targeted for data abstraction from the UCI NMC database and PRO-
ACT database:  
• Age 
• Smoking status 
• Comorbidities restricting lung function 
• Time since diagnosis 
• Time since symptom onset 
• Time to NIV initiation 
• Time to death, if applicable 
• ALSFRSr scores 
• Seated %FVC scores 
2.6 Study Endpoints 
 Since the average life expectancy of a person with ALS averages about two to five years 
from the time of diagnosis, identifying links that are predictors of survival may help 
clinicians in initiating the palliative care previously discussed. As such, the following study 
endpoints were set under the premise of viable data from the UCI and PRO-ACT databases: 
• ALSFRSr slope of decline over time stratified within groups by site of onset (limb vs. 
bulbar) 
• FVC (%) slope of decline over time stratified within groups by site of onset (limb vs 
bulbar) 
2.7 Methods of Analysis 
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 Since this was a retrospective review of data, power and sample size calculations were 
not necessary to analyze the data. Statistical analysis was conducted using SPSS version 25.0 
(IBM, Inc., Armonk NY) and SAS version 9.4 (SAS Institute Inc., Cary NC) software. 
Descriptive statistics were used to determine the distribution between the following patient 
characteristics: age, sex, site of onset (limb or bulbar), race, ethnicity, and time to death. 
Additional descriptive statistics were used to observe the distribution of site of onset within sex, 
Caucasian race, and ethnicity. Bivariate correlations were used to test for significant correlation 
between disease-specific variables and age, sex, and race/ethnicity. Independent samples t-tests 
were used to determine the relationships between Riluzole use or site of onset against time to 
death. Univariate regression was employed to determine the average ALSFRSr score among the 
subjects. 
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RESULTS 
3.1 UCI NMC Dataset  
 The Honest Broker query identified 192 patients, but data abstraction was prematurely 
terminated because of access provisioning issues. Consequently, a total of 54 patients were 
reviewed and 25 met the inclusion criteria requiring a confirmed diagnosis and > 3 visits. The 
primary reason for exclusion was diagnosis misidentification in query’s target. (Figure 6, Figure 
7)  
Figure 6. UCI NMC: Excluded Cases 
                
Figure 7. UCI NMC: Excluded Cases - Other Diagnoses 
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 The data abstracted for included patients were as follows: site of onset, date of clinic 
visits, ALSFRSr scores, %FVC seated, race/ethnicity, symptom onset date, diagnosis date, age at 
diagnosis, and date of first documented NIV and/or PEG use (if applicable). The intervals 
between clinic visits varied between patients since appointments are dependent on patient and 
clinician availability, as well as insurance approval. To easily compare between subgroups, visit 
dates were adjusted (Figure 8) and a new variable was created to calculate the diagnostic delay 
which was defined as the difference, in days, from date of diagnosis to date of symptom onset.  
Figure 8. UCI NMC: Visit Date Adjustment 
  
 During the data abstraction phase, it was evident that the inconsistent recording of 
ALSFRSr scores would be a limiting factor in the overall data analysis. Among the 25 patients, 
only 55% of the expected ALSFRSr counts were present. The imputation method was considered 
as that is the most commonly used missing data method in ALS trials. However, since the sample 
size was smaller than anticipated, the analytical plan was modified to be predominantly focused 
on reporting observations.  
3.1.1 Demographics 
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 The average patient age was approximately 61 years (range: 35-83). In this random 
sampling of 25 patients, the ratio of bulbar- to limb-onset ALS was 1:1.3. Approximately 68% of 
patients had race or ethnicity documented in their records. (Table 1) Additionally, 48% had 
documented NIV use and 36% had documented PEG placement data with 100% of PEG patients 
using NIV.   
Table 1. UCI NMC: Demographics 
Race/Ethnicity n (%) 
Caucasian  11 (64.7) 
Pacific Islander 1 (5.9) 
Asian 2 (11.8) 
Hispanic or Latino* 3 (17.6) 
Table entries are sample size (%) out of 17; *unknown race 
3.1.2 Site of Onset 
 The average age of bulbar-onset patients was 65.2 years (range: 48-83), whereas the 
limb-onset patients were 58.9 years (range: 35-79). Patients with bulbar-onset ALS on average 
had a longer diagnostic delay than limb-onset ALS patients by approximately 129 days. 
Although this value was not statistically significant (p=.376), a 3-month difference is clinically 
relevant given the faster rate of decline usually seen in patients with bulbar-onset ALS. This 
difference was demonstrated by the faster time in the 17% lower mean FVC score (Figure 9) and 
faster time to NIV initiation and PEG placement from time of diagnosis. (Table 2)  
Table 2. UCI NMC: Mean Values by Site of Onset  
 Bulbar Limb p 
FVC (%)  70.1 87.1 .072 
NIV Initiation (days) 193 421 .302 
PEG Placement (days) 183 740 .224 
Table entries are mean; p-values computed using independent samples t-test  
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  On average, limb onset patients had a higher average FVC score and more documented 
FVC trials than bulbar onset patients. A total of 12 patients, 6 bulbar and 6 limb onset patients 
initiated NIV, but only half of the limb onset group went on to have PEG tubes placed.  
Figure 9. UCI NMC: FVC Decline by Site of Onset 
 
3.2 PRO-ACT Dataset Cleaning 
Although there were over 12,000 subjects in the PRO-ACT dataset, initial review of the 
various files that compose the database revealed large amounts of missing data per subject. The 
target subjects for inclusion in the final analysis required a robust dataset with as minimal 
missing values as possible.  
 Prior to 1999, the ALSFRS scale only had one question related to respiratory function, 
thus giving disproportionate weight to limb and bulbar dysfunction. The ALSFRSr incorporated 
additional assessments of dyspnea, orthopnea, and the need for ventilatory support. Given the 
importance of respiratory function in ALS, it was important to have subjects that were 
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administered the ALSFRSr instead of the ALSFRS. Subjects with ALSFRSr data and three or 
more visits in the PRO-ACT dataset were extracted; the resulting aggregate file revealed 3374 
viable cases with 30,978 data points.  
 As mentioned before, FVC is an objective measure of respiratory function and its decline 
is indicative of diaphragmatic weakness. It serves as a key clinical tool for initiating NIV earlier 
on during the disease when the survival benefit is higher. The aggregate data extrapolation for all 
subjects with more than three visits revealed 5014 cases for use.  
 After preparing both aggregate ALSFRSr and FVC files, the two datasets were compared 
to identify match cases. Match cases were defined as subjects that had ALSFRSr data, FVC data, 
and more than three visits for analysis. The resulting PRO-ACT Matched Cases file identified 
375 subjects that met the inclusion criteria. However, it was at this point that the FVC inclusion 
parameter was re-visited. In addition to the absence of respiratory-restricting comorbidity data, 
there was a significant amount of missing data points within each case which risked 
compromising the integrity of conclusions drawn from the analyses. (Table 3) Consequently, the 
analytical plan was amended to forgo FVC analysis and proceed solely with the cases identified 
in the ALSFRSr aggregate file. Figure 10 details the datasets selected for these subjects that were 
merged into one file for the full analysis. The variables were compared against the ‘Subject ID’ 
variable to identify the extent of missing data; the ‘Diagnostic Delay’ variable was calculated 
using the absolute value of the difference between the ‘Symptom Onset to Trial Start’ and 
‘Diagnosis to Trial Start’ variables, in days.  
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Figure 10. PRO-ACT: Dataset Variables 
 
Table 3. PRO-ACT: Missing Data 
Variable n 
Site of Onset 444 (13.2) 
Diagnostic Delay 1380 (40.9) 
Age 678 (20.1) 
Gender 0 (0.0) 
Riluzole Use 619 (18.4) 
Ethnicity 1806 (53.5) 
Race 1720 (51.0) 
Death Report 1796 (53.2) 
Table entries are sample size (%) missing out of 3374 patients 
3.2.1 Demographics  
 The average age of the participants was approximately 56 years (range: 18-82) with a 
1.7:1 male to female ratio. Of the 3374 subjects, only 2930 (86.4%) had data recorded for site of 
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•Time to 
Death After 
Trial Start 
(days)
ALS History
Site of Onset
Symptom 
Onset to Trial 
Start (days)
Diagnosis to 
Trial Start 
(days)
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symptom onset. Within this group, 30.5% of the 1112 females had bulbar-onset ALS; whereas 
among 1818 males, only 18.7% had bulbar-onset ALS. (Figure 11) Approximately 50% of the 
3374 subjects did not have race recorded. Among the 1671 subjects with race recorded, 94.6% 
were categorized as Caucasian, leaving 3.6% as either Black/African American or Asian; the 
remaining 1.8% were categorized as unknown. (Table 4) The reporting of Hispanic/Latino 
ethnicity was missing in over 50% of the included cases. The frequency of Hispanic/Latino 
ethnicity, regardless of race, was reported as 4.7% Hispanic/Latino and 95.3% non-
Hispanic/Latino. Given the large disparity between Caucasian and non-Caucasian races in this 
dataset, the analysis was conducted once more without any ALSFRSr and minimum number of 
visit restrictions. By removing these restrictions, Caucasians comprised 62.6% of the total PRO-
ACT database, while Black/African American and Asian subjects made up 16.5%; the remaining 
20.9% fell under other or unknown. The same was done for the ethnicity data which revealed 
that 81.7% of the PRO-ACT database was either unknown or missing ethnicity data.  
Table 4. PRO-ACT: Demographics 
Variable n (%) Mean 
Age (years)   
Female 990 (29.3) 57.8 
Male 1706 (50.6) 54.5 
Race   
American Indian/Alaska Native 0 - 
Asian 17 (0.5) - 
Black/African American 28 (0.8) - 
Hawaiian/Pacific Islander 15 (0.4) - 
Unknown 30 (0.9) - 
Caucasian 1581 (46.8) - 
Ethnicity   
Hispanic or Latino 74 (2.2) - 
Non-Hispanic or Latino 1494 (44.3) - 
Table entries are sample size (%) out of 3374 patients  
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Figure 11. PRO-ACT: Site of Onset by Gender 
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3.2.2 Enrollment Age  
Compared to the bulbar-onset patients where the average age was 58.3 years (CI: 57.4-
59.2), the limb-onset patients had a younger average age of 54.8 years (CI: 54.2-55.3). (Figure 
12)   
Figure 12. Site of Onset vs Age 
   
3.2.3 Gender  
An inter-gender comparison, stratified by site of onset, of the mean survival times from 
diagnosis to death revealed that bulbar- and limb-onset females lived longer than males by 77 
(p=.097) and 20 days (p=.544), respectively. The intra-gender comparison demonstrated that 
limb-onset patients, regardless of gender, lived longer on average. However, there was a 
significant mean difference in time from diagnosis to death for males by approximately 115 days 
(p=.003). (Figure 13)   
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Figure 13. PRO-ACT: Kaplan-Meier Survival Curve for Males 
  
3.2.4 ALSFRSr  
The average first and last documented ALSFRSr scores for all patients in the dataset were 
37.8 and 26.4, respectively. Among the 3374 patients, the average length of study participation 
was 377 days corresponding with a 13-point overall rate of decline on the 48-point scale. Upon 
examination, 24 patients were identified as unusual cases because they did not have any change 
in ALSFRSr scores. The first 6 were grouped as probable early terminations who were not in a 
study long enough, only 37-95 days, for the outcome measure to detect functional change. The 
other 18 patients were in a study for at least 109 days and at most 739 days; the average 
ALSFRSr score in this group was 44 without any change in 327 days. An adjusted analysis was 
done excluding the latter 18 patients and retaining the former 6 patients. The adjusted average 
length of study participation was 114 days corresponding with a 6-point overall rate of decline. 
(Figure 14, Figure 15) 
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Figure 14. PRO-ACT: ALSFRSr Score Over Time in Limb-Onset ALS 
      
Figure 15. PRO-ACT: ALSFRSr Score Over Time in Bulbar-Onset ALS 
 
3.2.5 Mortality  
Vital status was reported for 1578 patients, 728 of whom passed away during or shortly 
after study participation. Based on the 598 patients with more specific death data available, the 
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average time to death was 2.6 years (IQR: 1.8-3.2) after disease onset. Despite the increased 
mortality risk associated with bulbar-onset ALS, only 17.2% of the bulbar-onset subjects died 
compared to the 82.8% documented as limb-onset. As expected, the average time to death for 
subjects with limb-onset compared to bulbar-onset ALS was significantly longer. However, the 
diagnostic delay was not significantly different between the two groups. (Table 5) It is possible 
that there were more deaths in the bulbar-onset group that was not captured as it should have 
been, or these subjects withdrew from the study beforehand in which case it would not be part of 
this database. 
Table 5. PRO-ACT: Time to Death Stratified by Site of Onset 
 
Limb-Onset 
(N=441) 
Bulbar-Onset 
(N=145) 
p 
Diagnostic Delay  315 286 .122 
Symptom Onset to Death  970 860 .001 
Diagnosis to Death  655 575 .004 
Table entries are mean, in days; p-values computed using independent samples t-test 
3.2.6 Study Treatment Group  
Since the PRO-ACT database contains data points from subjects that participated in a 
clinical trial, the potential effects of study treatment assignments were explored. Independent 
samples t-test was used to identify mean difference in survival between the active and placebo 
groups across the 23 clinical trials that composed the dataset. Equal variances were assumed 
between the two groups which showed the subjects who were in the placebo group had a mean 
difference in time to death of 214 days compared to the active group whose median time to death 
was 824 days [CI: -412 to -15, p=.036].  
3.2.7 Riluzole 
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Although there was a great deal of missing data, the use of Riluzole was one of the most 
robust variables in the PRO-ACT database. Riluzole use was collected for 92.4% of the 10,723 
subjects in the database. Since most ALS clinical trials include inclusion criterion requiring a 
stable Riluzole status (taking or not taking) for at least 30 days prior to study screening, an 
independent samples t-test was conducted for all subjects with both Riluzole and death data that 
had at least 3 study visits to detect possible effect on time to death. The ratio between the two 
subgroups stayed consistent as the sample size narrowed. (Figure 16) The average time to death 
(in days) for subjects using Riluzole was approximately 408 days compared to 450 days [CI: -4 
to 88] for those who were not taking it. The mean difference in time to death was not statistically 
significant (p=.073).  
Figure 16. PRO-ACT: Riluzole Use 
 
3.3 Prospective Online ALS Questionnaire 
A total of 32 respondents completed the online questionnaire, which was available for 30 
days. There were 10 respondents who required assistance from a caregiver to input their 
responses on their behalf.  
Riluzole 
Data: 8,817
• Taking - 79%
• Not Taking - 21%
+ ALSFRSr 
Data: 2755
• Taking - 80%
• Not Taking - 20%
+ Death 
Data: 463
• Taking - 77%
• Not Taking - 23% 
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3.3.1 Demographics 
 The average age was 66 years (range: 45-95) for both men (n=17) and women (n=15). 
Women reported a slightly higher diagnostic delay (10.8 months) than men did (8.1 months). 
Respondents were asked to provide their race by selecting all of the following that applied: 
European, Middle Eastern, North African, Black or African American, Asian Indian, Chinese, 
Filipino, Japanese, Korean, Vietnamese, Other Asian, Native Hawaiian or Other Pacific Islander, 
Cuban, Mexican, Puerto Rican, South or Central American, American Indian or Alaska Native. 
The responses received fell into six distinct categories, two of which were biracial. (Table 6)  
3.3.2 Site of Onset 
After recalling their first symptom(s), 10 cited ‘difficulty speaking’ or ‘difficulty 
breathing’ as the main symptom that lead them to seek out a physician’s evaluation. (Figure 17) 
These 10 were categorized as bulbar-onset ALS, while the 22 respondents who cited ‘foot drop’, 
‘muscle twitching’ or ‘muscle weakness’ as the main symptom were categorized as limb-onset 
ALS. The gender ratio as equal in the bulbar-onset group, but 1:1.75 in the limb-onset group 
with higher male prevalence. (Table 6)  
Figure 17. Online Questionnaire: Reported First Symptom(s) 
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Table 6. Online Questionnaire: Race Distribution by Site of Onset with Gender Ratio 
 Limb-Onset Bulbar-Onset Male: Female 
European  15 8 12:11 
Black or African American  1 0 1:0 
Mexican  3 0 1:2 
South or Central American 1 1 1:1 
Chinese & Native Hawaiian  
or Other Pacific Islander 
1 0 1:0 
European & American Indian 
or Alaska Native 
1 1 2:0 
 
3.3.3 Diagnostic Journey 
A quarter of the respondents reported themselves as diagnosed less than one year ago, 
while 12% reported they were diagnosed upwards of five years ago. (Figure 18) Prior to getting 
diagnosed, 54% of respondents were misdiagnosed and managed for another disease at least 
once; 16% were misdiagnosed more than two times.  
Figure 18. Online Questionnaire: ALS Diagnosis Duration 
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DISCUSSION 
4.1 The Comparison to National Averages  
The average age in the PRO-ACT database aligns with the current national average of 55 
years and less than 50% of the 3,374 patients survived past five years from symptom onset. 
However, there was a higher incidence of males with ALS and the racial prevalence aligns with 
the study conducted at MGH which observed higher rates of ALS among Caucasians compared 
to other racial groups. The concurrence between that study and this one is to be expected given 
the disproportionate ratio of Caucasian subjects to non-Caucasian subjects. As demonstrated by 
Rochon et al, representation of minorities in clinical trials remains wanting. Their data indicated 
that approximately 82% of randomized control trials participants were “White (non-Hispanic)” 
relative to 72% who reported to be “White” in the 1999 U.S. Census Bureau. By contrast, about 
27% of the 1999 US population reported as “Black (non-Hispanic), Asian and Pacific Islander, 
and Hispanic”, but only 13% reported as trials participants. (26)  
 Comparatively, within the UCI dataset and the Online Questionnaire respondents, the 
mean age was higher than the national average by 6 and 11 years, respectively. Although the 
Caucasian prevalence was not as high as what was reported in the PRO-ACT database, it was 
still the most prevalent group. It is difficult to rule out the effect of the small sample sizes from 
the UCI dataset and Online Questionnaire dataset, 25 and 32, respectively. In general, minorities 
have less access to healthcare and mistrust in the medical system. Consequently, they are less 
likely to participate in clinical trials due to a lack of awareness, misperceptions about them, and 
overall lack of knowledge to make an informed decision to participate in one. Additionally, 
unlike the PRO-ACT dataset, the former two datasets had a relatively equal incidence of ALS 
between genders.  
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4.2 The Role of Patient Characteristics  
 Although the PRO-ACT analyses demonstrated an increased incidence of ALS in non-
minorities, a reliable conclusion regarding the rate of incidence and mortality between 
racial/ethnic groups was not possible because of the small group of minorities in the database. 
The gap was narrowed in the UCI and Online Questionnaire datasets, but vital status was often 
out-of-date in the clinic dataset and not applicable in the live patient sampling.  
4.3 The Value of Prospective Data Collection  
 Overall, the Online Questionnaire dataset successfully demonstrated a decreased mean 
diagnostic delay compared to the PRO-ACT dataset and comparative studies as well as a 
primarily Caucasian prevalence.  
4.3.1 Redefining Caucasian Terminology  
Currently the FDA guidelines define Caucasian as a person having origins in any of the 
original peoples of Europe, the Middle East, or North Africa. (27) The environmental factors 
(e.g., political, geographic, economic) are drastically different between these regions, but for 
statistical inferences they are always grouped together. More sensitive race/ethnicity results may 
be acquired with the use of more specific Caucasian terms. 
4.4 The Significance of Missing Data 
Clinical trial designs are robust to generate data that effectively proves or disproves the 
hypothesis. Nonetheless despite best efforts to minimize it, missing data happens for several 
reasons: duration of trial, outcome assessment difficulty, study protocol adherence, poor 
communication with study subjects. (28) Throughout the analyses, the biggest limitation was 
missing data points within the datasets which limited the availability of cases for evaluation. 
Often these cases were missing values within an outcome. For example, the standard FVC test 
34 
 
result is the highest FVC percent of three attempts. An overwhelming number of tests were 
missing values for individual attempts, predicted normal, and/or percent predicted. 
Missing data was not unique to the PRO-ACT database. While conducting the review of 
the patients within the UCI NMC database, missing death data was one of the most frequent 
findings. Checking the National Death Index (NDI) is a possible means for acquiring a more 
accurate and robust report of deaths; however, as the subjects in the PRO-ACT database were 
part of clinical trials, all data was de-identified. In the past few years, capturing Hispanic/Latino 
ethnicity has been emphasized more; however, in both databases, it was infrequently recorded. In 
the PRO-ACT database, the lack of decline among 18 patients makes it probable that the 
imputation method is used for the ALSFRSr database. Although the UCI NMC database had 
missing FVC data, the imputation method was not used in the analysis to avoid impacting the 
results as was the case with the PRO-ACT database until the 18 patients were extracted.  
Missing data corrupts studies, introduces bias, invalidates conclusions, and alters the 
original statistical plan. However, patients with missing data cannot be completely excluded 
either because it affects the study power and ignores potential outlier values that narrow the 
confidence interval. Missing data can be classified into three recognized types:  
1) Missing completely at random (MCAR): there are no systematic differences between 
the missing values and the observed values, e.g., FVC values are missing because the 
spirometer was not working 
2) Missing at random (MAR): the systematic difference between the missing values and 
the observed values can be explained by differences in observed data, e.g., missing 
FVC values are missing because the patient refused to do the assessment after 
initiating NIV 
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3) Missing not at random (MNAR): even after differences in observed data are 
considered, the systematic differences remain between missing and observed values, 
e.g., patients with low FVC values are more likely to miss visits because they are 
more disabled by the disease 
A crucial part of a study’s design is how missing data will be addressed. MCAR or MAR 
type data are less likely to occur and can be ignored; however, MNAR provides a critical look 
into the population being studied as well as insight for future studies. There are many methods to 
take care of missing data, each with their own merits and draw backs.  
 The combination of electronic medical records and historical clinical trial repositories 
present a wealth of data that is otherwise nearly impossible to come by in the rare disease setting. 
Using these data banks may engender future clinical trials with more robust analytical plans 
powered by smaller sample sizes. However, the validity of any conclusions drawn utilizing such 
methods are questionable if a corrective action plan is not implemented to address the missing 
data and prevent future oversight. There are several strategies to reduce missing data, including: 
increasing structured data documentation, reducing data input errors, and utilization of natural 
language processing (NLP). (25) The same missing data mitigation strategy can be employed for 
both EMR and clinical trials.  
4.5 The Effect of Investigational Products 
 In the past 20 years, over 50 clinical trials have been conducted to investigate 60 
molecules, but the overwhelming majority have failed to demonstrate clinical efficacy. (29) Of 
these 50 trials, 23 of them contributed data to the PRO-ACT database. 
 Although the trials failed, the tested compounds were not directly associated with 
contributing to disease progression. Yet, there is a statistically significant difference in the time 
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to death between the active drug and placebo groups with survival favoring the placebo group. A 
possible explanation could be experiencing side effects associated with the active investigational 
product diminishing the overall quality of life, which in turn contributed to disease progression.  
 Another possible explanation to take into consider is the placebo response: the 
physiological response to the inactive arm. (30) One of the contributors for this effect are 
therapeutic interactions with staff members during the study. Clinical trial subjects receive more 
face-to-face interaction with clinicians and other multidisciplinary members, as well as 
encouragement and support from study staff. Another contributor is the increased 
expectation/hope of treatment benefit that patients experience. Patient expectations about trial 
outcomes have shown to be an important mediator of the placebo effect. (31) This is even more 
pronounced in trials with competitive enrollment, like most ALS trials, where clinicians feel 
somewhat compelled to make the study more attractive to potential participants by highlighting 
the potential benefits of participation. Prior systematic reviews have also identified placebo 
response to be higher in studies with outcomes based on questionnaires instead of clinical 
biomarkers. (32) Of the 23 drugs that advanced into further clinical development, 11 of them 
used the ALSFRSr as the primary endpoint. Placebo response is notably more pronounced in 
trials where outcomes are measured by patient reported outcomes to those assessed by clinicians. 
(33) 
4.6 The Importance of Unavailable Data  
There were several data points that are collected as part of ALS clinical trials, including 
the ones that are in the PRO-ACT database, but were not available for analysis. The most notable 
data points were ‘smoking status’, ‘comorbidities restricting lung function’, and ‘NIV initiation 
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timepoint.’ Understandably, not all medical history points can be included within the database. 
However, these variables impact the accuracy of disease progression predictive modeling.   
Since the mortality risk for bulbar-onset ALS patients is adjusted with the monthly 
survival benefit from non-invasive ventilation (NIV), it would have been beneficial to be able to 
factor in NIV use as well. Unfortunately, this key variable was not captured and thus could not 
be analyzed. Previous studies estimate a 3.5-fold survival benefit with the use of NIV across all 
ALS patients, which is of importance in bulbar-onset ALS since it has twice the monthly 
mortality rate once the respiratory system is affected by the disease. (17) 
4.7 The Complexities of Late-Stage Clinical Trials  
Roughly 50% of investigational drugs fail in late-stage clinical development due to 
inadequate efficacy and/or safety concerns. (34) In an assessment of 640 phase 3 trials, the 
factors most often associated with likelihood of FDA approval were orphan designation, cancer 
drugs, and larger sponsor size (annual gross revenues > $1 billion USD). The 1983 Orphan Drug 
Designation Act is a fast-track distinction for novel therapies created by the FDA to promote 
medical advancement for rare disease populations. 
Compared to nonorphan drugs, orphan drugs are more likely to be approved based on 
small, single-arm trials which attempt to mitigate the enrollment challenge with rare diseases. In 
2009, Mitsumoto et al compared drugs with and without orphan indications and identified the 
elements of clinical trials that received FDA approvals of drugs within neurological indications. 
The group found that all groups without an orphan indication included at least two randomized, 
double-blind, placebo-controlled trials. In contrast, only 32% of orphan indications had at least 
two similar trials but conducted 33 pivotal trials for the 19 drugs approved with orphan 
indication. Of the 33 trials, 33% did not have a placebo control, 27% were not double-blind, and 
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12% were not randomized at all. Comparatively, drugs approved without orphan indication had 
more pivotal trials and a larger mean trial size. (35)  
Small, single-arm trials increase the chance for false-positive results and bypasses an 
opportunity for in-depth understanding of the drug in development. This is especially true in 
diseases such as ALS where the variability in disease course poses a complication in trial design. 
Since time is used as a proxy for disease progression, the power to detect treatment effect can be 
reduced by the patients that are slow progressors who will have little change during participation. 
Consequently, most ALS trials now have inclusion criteria that exclude this subset thus 
foregoing the effect of a proposed investigational drug in a real-world setting. Rather than 
excluding based on disease variability, disease staging provides an alternate approach for 
measure disease progression regardless of its nature in any one individual.  
 One of the most widely used ALS staging systems is King’s clinical stages which can be 
derived from standard clinical observations and estimated from the revised ALSFRS-r. It ranges 
from 1 (early disease) to 4 (late disease), with stage 5 being death. The high correspondence 
between the ALSFRSr and actual clinical stage based on examination findings make King’s 
stage useful for retrospective analyses. The clinical trial for Riluzole, which received FDA 
approval in 1995, demonstrated a 35% reduction in mortality at a dose of 100 mg per day. In 
2018, King’s staging was used to retrospectively analyze the results from the original dose-
ranging study to understand the relationship between the survival benefit of Riluzole and disease 
stage. The study found that the survival benefit of Riluzole is achieved by extending stage 4, not 
by prolonging stages 2 or 3, or overall slowing the disease. (36) Stage 4 is last living stage of the 
disease with the highest disability. Although it could be argued that NIV and PEG are also used 
at stage 4 and prolong this stage, both provide functional benefit by alleviating respiratory 
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discomfort and nutritional failure, respectively. In contrast, the Riluzole trial failed to show an 
overall effect on function. Ultimately patients should be counselled with this information 
because it affects their quality of life to make a fully informed decision.  
The push for pharmaceutical innovation has opened the door for smaller-scale trials and 
abbreviated late stage testing. However, robust drug development is the key to preventing 
widespread use of ineffective, or even harmful drugs. The shift should be directed at improving 
methods of validity that serve as the bridge between preclinical to clinical. (34) This is of 
importance in rare diseases, like ALS, where time is crucial leaving patients vulnerable to 
rushing healthcare decisions. 
 False or incomplete data is the root of uninformed or misinformed decisions. However, 
the technology behind modern big data analytics has reduced this inherent risk that accompanies 
working with data thus allowing for confidence in more accurate data. Although large clinical 
trial data repositories are valuable, in the setting of rare diseases, natural history databanks may 
be more appropriate for big data analysis. Natural history studies allow researchers to gain a 
better understanding of a disease’s progression, how it is managed by clinicians, and what unmet 
needs exist. These studies may also help identify environmental factors, biomarkers, and other 
previously unknown risk factors that can guide which drugs are targeted to prevent or slow the 
disease. Relevant data points need to be agreed upon among the ALS community of researchers, 
physicians, and community experts (i.e., patients and support); starting the conversation already 
raises much needed awareness for the ALS community. Ideally, every ALS patient who is seen 
at an ALS center of excellence should be consented to contribute relevant de-identified data at 
every clinic visit throughout their disease course. A standardized natural history databank can 
allow for calculated prevalence that is more inclusive of minorities and may help establish good 
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standards in disease management. Furthermore, if natural history data is comparable with data 
from a clinical trial, then the placebo group can be smaller or eliminated entirely. It not only 
reduces the costs associated with conducting clinical trials, but can ameliorate the time to study 
enrollment completion. Ultimately, big data can lead clinical researchers to substantial 
breakthroughs and empower key decision-makers (e.g., patients, clinicians) to making decisions 
with more certainty. 
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